family_id
int64 1
1.1k
| family_type
stringclasses 9
values | family_name
stringclasses 590
values | target_id
int64 1
3.29k
| target_name
stringlengths 3
122
| ligand_id
int64 1
13.4k
| ligand_name
stringlengths 2
141
| ligand_type
stringclasses 6
values | interaction_id
int64 1
90.9k
| interaction_type
stringclasses 11
values | interaction_action
stringclasses 25
values | ligand_approved
bool 2
classes | ligand_approval_source
stringclasses 440
values | ligand_pubchem_sid
float64 53.8M
491M
⌀ | interaction_primary_target
bool 2
classes | interaction_affinity_median
float64 0.3
13
⌀ | interaction_affinity_units
stringclasses 7
values | reference_id
float64 21
47.8k
⌀ | reference_type
stringclasses 4
values | reference_title
stringclasses 714
values | reference_article_title
stringlengths 0
409
⌀ | reference_pubmed_id
float64 156k
38.9M
⌀ | reference_doi
stringclasses 154
values | reference_pmc_id
stringlengths 7
11
⌀ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
102 | nhr | 0B. DAX-like receptors | 636 | SHP | 8,838 | compound 10 [PMID: 18759424] | Synthetic organic | 82,888 | None | Binding | false | 252,827,495 | false | 6.3 | pIC50 | 29,925 | Journal | J Med Chem | Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity. | 18,759,424 | null | PMC4097887 |
|
922 | enzyme | 1.1.1.42 Isocitrate dehydrogenases | 2,885 | isocitrate dehydrogenase (NADP(+)) 2 | 8,960 | enasidenib | Synthetic organic | 83,689 | Inhibitor | Binding | true | FDA (2017) | 310,264,741 | false | null | - | 30,371 | Patent | null | Therapeutically active compounds and their methods of use. | null | null | null |
922 | enzyme | 1.1.1.42 Isocitrate dehydrogenases | 2,885 | isocitrate dehydrogenase (NADP(+)) 2 | 12,340 | LY3410738 | Synthetic organic | 89,098 | Inhibitor | Inhibition | false | 479,821,131 | false | 6.05 | pIC50 | 44,570 | Patent | null | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | null | null | null |
|
922 | enzyme | 1.1.1.42 Isocitrate dehydrogenases | 2,885 | isocitrate dehydrogenase (NADP(+)) 2 | 10,663 | vorasidenib | Synthetic organic | 87,066 | Inhibitor | Inhibition | false | 404,859,110 | false | null | - | 38,752 | Journal | ACS Med Chem Lett | Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. | 32,071,674 | 10.1021/acsmedchemlett.9b00509 | null |
|
922 | enzyme | 1.1.1.42 Isocitrate dehydrogenases | 2,884 | isocitrate dehydrogenase (NADP(+)) 1 | 9,217 | ivosidenib | Synthetic organic | 83,688 | Inhibitor | Inhibition | true | FDA (2018), EMA (2023) | 315,661,293 | true | null | - | 31,205 | Patent | null | Therapeutically active compounds and their methods of use | null | null | null |
922 | enzyme | 1.1.1.42 Isocitrate dehydrogenases | 2,884 | isocitrate dehydrogenase (NADP(+)) 1 | 12,340 | LY3410738 | Synthetic organic | 89,097 | Inhibitor | Inhibition | false | 479,821,131 | false | 8.2 | pIC50 | 44,570 | Patent | null | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | null | null | null |
|
922 | enzyme | 1.1.1.42 Isocitrate dehydrogenases | 2,884 | isocitrate dehydrogenase (NADP(+)) 1 | 9,240 | AGI-5198 | Synthetic organic | 83,752 | Inhibitor | Inhibition | false | 315,661,315 | true | 4.89 | pKi | null | null | null | null | null | null | null |
|
922 | enzyme | 1.1.1.42 Isocitrate dehydrogenases | 2,884 | isocitrate dehydrogenase (NADP(+)) 1 | 12,340 | LY3410738 | Synthetic organic | 89,096 | Inhibitor | Inhibition | false | 479,821,131 | false | 6.98 | pIC50 | 44,570 | Patent | null | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | null | null | null |
|
922 | enzyme | 1.1.1.42 Isocitrate dehydrogenases | 2,884 | isocitrate dehydrogenase (NADP(+)) 1 | 10,319 | olutasidenib | Synthetic organic | 86,199 | Inhibitor | Inhibition | true | FDA (2022) | 381,745,000 | false | null | pIC50 | 37,387 | Patent | null | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | null | null | null |
922 | enzyme | 1.1.1.42 Isocitrate dehydrogenases | 2,884 | isocitrate dehydrogenase (NADP(+)) 1 | 11,884 | safusidenib | Synthetic organic | 88,488 | Inhibitor | Inhibition | false | 461,663,440 | false | 6.89 | pIC50 | 43,349 | Journal | Mol Cancer Ther | A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model. | 31,727,689 | null |
||
922 | enzyme | 1.1.1.42 Isocitrate dehydrogenases | 2,884 | isocitrate dehydrogenase (NADP(+)) 1 | 10,663 | vorasidenib | Synthetic organic | 87,065 | Inhibitor | Inhibition | false | 404,859,110 | false | null | - | 38,752 | Journal | ACS Med Chem Lett | Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. | 32,071,674 | 10.1021/acsmedchemlett.9b00509 | null |
|
899 | enzyme | 1.13.11.- Dioxygenases | 2,829 | indoleamine 2,3-dioxygenase 1 | 9,019 | navoximod | Synthetic organic | 83,385 | Inhibitor | Inhibition | false | 315,661,104 | false | 8.24 | pKi | 38,078 | Journal | J Med Chem | Discovery of Clinical Candidate (1<i>R</i>,4<i>r</i>)-4-((<i>R</i>)-2-((<i>S</i>)-6-Fluoro-5<i>H</i>-imidazo[5,1-<i>a</i>]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1. | 31,264,862 | null |
||
899 | enzyme | 1.13.11.- Dioxygenases | 2,829 | indoleamine 2,3-dioxygenase 1 | 9,750 | necrostatin-1 | Synthetic organic | 84,754 | Inhibitor | Inhibition | false | 354,702,223 | false | 4.94 | pKi | 34,030 | Journal | Nat Med | Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. | 15,711,557 | null | null |
|
899 | enzyme | 1.13.11.- Dioxygenases | 3,019 | indoleamine 2,3-dioxygenase 2 | 10,126 | tryptanthrin 5i | Synthetic organic | 85,686 | Inhibitor | Inhibition | false | 381,118,836 | false | 5.74 | pIC50 | 36,340 | Journal | Eur J Med Chem | Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors. | 27,475,108 | null |
||
899 | enzyme | 1.13.11.- Dioxygenases | 3,019 | indoleamine 2,3-dioxygenase 2 | 10,126 | tryptanthrin 5i | Synthetic organic | 85,685 | Inhibitor | Inhibition | false | 381,118,836 | false | 6.01 | pKi | 36,340 | Journal | Eur J Med Chem | Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors. | 27,475,108 | null |
||
899 | enzyme | 1.13.11.- Dioxygenases | 3,019 | indoleamine 2,3-dioxygenase 2 | 12,668 | example 184 [WO2014186035] | Synthetic organic | 89,777 | Inhibitor | Inhibition | false | 483,123,216 | false | 6 | pIC50 | 45,531 | Patent | null | Inhibitors of the kynurenine pathway | null | null | null |
|
899 | enzyme | 1.13.11.- Dioxygenases | 2,829 | indoleamine 2,3-dioxygenase 1 | 10,126 | tryptanthrin 5i | Synthetic organic | 85,689 | Inhibitor | Inhibition | false | 381,118,836 | false | 6.99 | pIC50 | 36,340 | Journal | Eur J Med Chem | Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors. | 27,475,108 | null |
||
899 | enzyme | 1.13.11.- Dioxygenases | 2,829 | indoleamine 2,3-dioxygenase 1 | 10,126 | tryptanthrin 5i | Synthetic organic | 85,688 | Inhibitor | Inhibition | false | 381,118,836 | false | 7.27 | pKi | 36,340 | Journal | Eur J Med Chem | Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors. | 27,475,108 | null |
||
899 | enzyme | 1.13.11.- Dioxygenases | 2,829 | indoleamine 2,3-dioxygenase 1 | 8,224 | tryptanthrin | Natural product | 81,828 | Inhibitor | Inhibition | false | 249,565,904 | false | 5.32 | pKi | 27,057 | Journal | J Med Chem | Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. | 24,099,220 | null | null |
|
899 | enzyme | 1.13.11.- Dioxygenases | 2,829 | indoleamine 2,3-dioxygenase 1 | 9,565 | PF-06840003 | Synthetic organic | 84,344 | Inhibitor | Inhibition | false | 336,446,951 | false | 6.82 | pIC50 | 33,072 | Patent | null | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors. | null | null | null |
|
899 | enzyme | 1.13.11.- Dioxygenases | 2,887 | tryptophan 2,3-dioxygenase | 9,019 | navoximod | Synthetic organic | 86,538 | Inhibitor | Inhibition | false | 315,661,104 | false | 6 | pIC50 | 35,557 | Journal | J Med Chem | Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway. | 26,207,924 | null |
||
899 | enzyme | 1.13.11.- Dioxygenases | 2,887 | tryptophan 2,3-dioxygenase | 9,016 | LM10 | Synthetic organic | 83,380 | Inhibitor | Inhibition | false | 315,661,101 | true | 5.25 | pKi | 30,562 | Journal | Proc Natl Acad Sci USA | Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. | 22,308,364 | null | PMC3289319 |
|
899 | enzyme | 1.13.11.- Dioxygenases | 2,887 | tryptophan 2,3-dioxygenase | 9,016 | LM10 | Synthetic organic | 83,381 | Inhibitor | Inhibition | false | 315,661,101 | true | 6.21 | pIC50 | 30,562 | Journal | Proc Natl Acad Sci USA | Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. | 22,308,364 | null | PMC3289319 |
|
899 | enzyme | 1.13.11.- Dioxygenases | 2,887 | tryptophan 2,3-dioxygenase | 9,016 | LM10 | Synthetic organic | 83,382 | Inhibitor | Inhibition | false | 315,661,101 | false | 5.71 | pIC50 | 30,562 | Journal | Proc Natl Acad Sci USA | Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. | 22,308,364 | null | PMC3289319 |
|
899 | enzyme | 1.13.11.- Dioxygenases | 2,887 | tryptophan 2,3-dioxygenase | 9,016 | LM10 | Synthetic organic | 83,380 | Inhibitor | Inhibition | false | 315,661,101 | true | 5.25 | pKi | 30,563 | Journal | J Med Chem | Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. | 21,726,069 | null | null |
|
899 | enzyme | 1.13.11.- Dioxygenases | 3,019 | indoleamine 2,3-dioxygenase 2 | 10,126 | tryptanthrin 5i | Synthetic organic | 85,687 | Inhibitor | Inhibition | false | 381,118,836 | false | 6.35 | pIC50 | 36,340 | Journal | Eur J Med Chem | Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors. | 27,475,108 | null |
||
899 | enzyme | 1.13.11.- Dioxygenases | 2,829 | indoleamine 2,3-dioxygenase 1 | 8,225 | 1-methyl-L-tryptophan | Synthetic organic | 81,829 | Inhibitor | Inhibition | false | 249,565,905 | false | 4.37 | pKi | 27,057 | Journal | J Med Chem | Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. | 24,099,220 | null | null |
|
899 | enzyme | 1.13.11.- Dioxygenases | 2,829 | indoleamine 2,3-dioxygenase 1 | 8,227 | amg-1 | Synthetic organic | 81,830 | Inhibitor | Inhibition | false | 249,565,907 | false | 5.52 | pIC50 | 27,060 | Journal | Biochim Biophys Acta | Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. | 21,835,273 | null | null |
|
899 | enzyme | 1.13.11.- Dioxygenases | 2,829 | indoleamine 2,3-dioxygenase 1 | 8,222 | beta-carboline | Synthetic organic | 81,831 | Inhibitor | Inhibition | false | 249,565,902 | false | 0.92 | pKi | 27,062 | Journal | Bioorg Med Chem | Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors. | 21,269,836 | null | null |
|
899 | enzyme | 1.13.11.- Dioxygenases | 2,829 | indoleamine 2,3-dioxygenase 1 | 10,682 | compound 8u [PMID: 31999451] | Synthetic organic | 87,100 | Inhibitor | Inhibition | false | 404,859,129 | false | 7.1 | pKd | 38,829 | Journal | J Med Chem | Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3. | 31,999,451 | null | null |
|
899 | enzyme | 1.13.11.- Dioxygenases | 2,829 | indoleamine 2,3-dioxygenase 1 | 8,221 | epacadostat | Synthetic organic | 81,826 | Inhibitor | Inhibition | false | 249,565,901 | true | 7.17 | pIC50 | 27,054 | Journal | J Med Chem | Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. | 19,507,862 | null | null |
|
899 | enzyme | 1.13.11.- Dioxygenases | 2,829 | indoleamine 2,3-dioxygenase 1 | 9,707 | linrodostat | Synthetic organic | 87,102 | Inhibitor | Inhibition | false | 348,353,666 | false | null | - | 38,831 | Journal | Proc Natl Acad Sci USA | Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form. | 29,531,094 | null |
||
899 | enzyme | 1.13.11.- Dioxygenases | 2,829 | indoleamine 2,3-dioxygenase 1 | 9,940 | LW106 | Synthetic organic | 85,196 | Inhibitor | Inhibition | false | 363,894,234 | false | 5.8 | pIC50 | 35,001 | Journal | Br J Pharmacol | LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment. | 29,722,898 | null | PMC6016675 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,673 | lysine demethylase 3A | 8,230 | IOX1 | Synthetic organic | 81,840 | Inhibitor | Inhibition | false | 249,565,910 | true | 7 | pIC50 | 27,117 | Journal | ChemMedChem | A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. | 24,504,543 | null | PMC4503230 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,671 | lysine demethylase 2A | 8,229 | IOX2 | Synthetic organic | 81,838 | Inhibitor | Inhibition | false | 249,565,909 | false | 7.28 | pIC50 | 27,116 | Journal | ACS Chem Biol | Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. | 23,683,440 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,671 | lysine demethylase 2A | 7,025 | daminozide | Synthetic organic | 79,347 | Inhibitor | Inhibition | false | 178,103,604 | false | 5.82 | pIC50 | 24,165 | Journal | J Med Chem | Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. | 22,724,510 | null | PMC4673902 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,669 | lysine demethylase 1A | 5,281 | tranylcypromine | Synthetic organic | 80,056 | Inhibitor | Inhibition | true | FDA (1961) | 178,101,964 | false | 4.4 | pIC50 | 24,161 | Journal | MBio | A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. | 23,386,436 | null | PMC3565832 |
869 | enzyme | 1.14.11.- Histone demethylases | 2,669 | lysine demethylase 1A | 11,516 | TAK-418 | Synthetic organic | 87,987 | Inhibitor | Inhibition | false | 441,604,888 | false | 8.54 | pIC50 | 41,977 | Journal | Sci Adv | LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models. | 33,712,455 | 10.1126/sciadv.aba1187 | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,669 | lysine demethylase 1A | 8,980 | RN-1 | Synthetic organic | 83,295 | Inhibitor | Inhibition | false | 310,264,760 | true | null | pIC50 | 30,419 | Journal | ACS Chem Neurosci | Brain-penetrant LSD1 inhibitors can block memory consolidation. | 22,754,608 | null | PMC3382965 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,669 | lysine demethylase 1A | 8,390 | ORY-1001 | Synthetic organic | 84,267 | Activator | Activation | false | 252,166,601 | true | 7.7 | pIC50 | 32,716 | Journal | Epigenomics | KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease. | 26,111,032 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,669 | lysine demethylase 1A | 7,024 | NCL-1 | Synthetic organic | 79,345 | Inhibitor | Inhibition | false | 178,103,603 | false | 5.8 | pIC50 | 24,162 | Journal | Bioorg Med Chem | Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor. | 21,227,703 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,669 | lysine demethylase 1A | 8,241 | GSK-LSD1 | Synthetic organic | 81,857 | Inhibitor | Inhibition | false | 249,565,921 | true | 7.8 | pIC50 | 27,143 | Webpage | null | GSK-LSD1 - a chemical probe for LSD1. | null | null |
||
869 | enzyme | 1.14.11.- Histone demethylases | 2,669 | lysine demethylase 1A | 9,116 | GSK2879552 | Synthetic organic | 83,517 | Inhibitor | Inhibition | false | 315,661,201 | false | 6.4 | pIC50 | 30,869 | Patent | null | Cyclopropylamines as lsd1 inhibitors | null | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,669 | lysine demethylase 1A | 11,284 | CC-90011 | Synthetic organic | 87,625 | Inhibitor | Inhibition | false | 434,321,719 | false | 9.52 | pIC50 | 40,730 | Journal | J Med Chem | Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1) | 33,034,194 | 10.1021/acs.jmedchem.0c00978 | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,669 | lysine demethylase 1A | 7,023 | OG-L002 | Synthetic organic | 80,055 | Inhibitor | Inhibition | false | 178,103,602 | false | 7.7 | pIC50 | 24,161 | Journal | MBio | A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. | 23,386,436 | null | PMC3565832 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,698 | PHD finger protein 8 | 7,025 | daminozide | Synthetic organic | 79,346 | Inhibitor | Inhibition | false | 178,103,604 | false | 6.26 | pIC50 | 24,165 | Journal | J Med Chem | Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. | 22,724,510 | null | PMC4673902 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,686 | lysine demethylase 7A | 7,025 | daminozide | Synthetic organic | 79,348 | Inhibitor | Inhibition | false | 178,103,604 | false | 5.68 | pIC50 | 24,165 | Journal | J Med Chem | Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. | 22,724,510 | null | PMC4673902 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,685 | lysine demethylase 6B | 12,807 | zavondemstat | Synthetic organic | 89,918 | Inhibitor | Inhibition | false | 483,123,355 | false | null | pIC50 | 45,828 | Patent | null | Histone demethylase inhibitors | null | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,685 | lysine demethylase 6B | 8,230 | IOX1 | Synthetic organic | 81,842 | Inhibitor | Inhibition | false | 249,565,910 | false | 5.8 | pIC50 | 27,117 | Journal | ChemMedChem | A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. | 24,504,543 | null | PMC4503230 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,685 | lysine demethylase 6B | 8,979 | GSK-J4 | Synthetic organic | 83,289 | Inhibitor | Inhibition | false | 310,264,759 | false | 5.07 | pIC50 | 30,418 | Journal | Nature | Inhibition of demethylases by GSK-J1/J4. | 25,279,926 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,685 | lysine demethylase 6B | 7,027 | GSK-J1 | Synthetic organic | 79,352 | Inhibitor | Inhibition | false | 178,103,606 | false | null | pIC50 | 24,169 | Journal | Nature | A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. | 22,842,901 | null | PMC4691848 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,685 | lysine demethylase 6B | 7,027 | GSK-J1 | Synthetic organic | 79,352 | Inhibitor | Inhibition | false | 178,103,606 | false | null | pIC50 | 30,418 | Journal | Nature | Inhibition of demethylases by GSK-J1/J4. | 25,279,926 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,685 | lysine demethylase 6B | 9,960 | compound 3 [PMID: 29633584] | Synthetic organic | 85,227 | Inhibitor | Inhibition | false | 374,883,847 | true | 5.82 | pIC50 | 35,098 | Journal | ChemMedChem | Virtual Fragment Screening Identification of a Quinoline-5,8-dicarboxylic Acid Derivative as a Selective JMJD3 Inhibitor. | 29,633,584 | null | PMC6055880 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,684 | lysine demethylase 6A | 10,141 | KDM5 inhibitor N71 | Synthetic organic | 85,721 | Inhibitor | Inhibition | false | 381,118,851 | false | 4.22 | pIC50 | 36,398 | Journal | J Med Chem | Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A. | 30,392,349 | null | PMC6467790 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,684 | lysine demethylase 6A | 8,979 | GSK-J4 | Synthetic organic | 83,288 | Inhibitor | Inhibition | false | 310,264,759 | false | 5.18 | pIC50 | 30,418 | Journal | Nature | Inhibition of demethylases by GSK-J1/J4. | 25,279,926 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,684 | lysine demethylase 6A | 7,027 | GSK-J1 | Synthetic organic | 83,287 | Inhibitor | Inhibition | false | 178,103,606 | false | 7.28 | pIC50 | 30,418 | Journal | Nature | Inhibition of demethylases by GSK-J1/J4. | 25,279,926 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,682 | lysine demethylase 5C | 7,026 | PBIT | Synthetic organic | 79,351 | Inhibitor | Inhibition | false | 178,103,605 | false | 5.31 | pIC50 | 24,166 | Journal | J Biol Chem | Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. | 23,408,432 | null | PMC3611010 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,682 | lysine demethylase 5C | 8,229 | IOX2 | Synthetic organic | 81,839 | Inhibitor | Inhibition | false | 249,565,909 | false | 6.8 | pIC50 | 27,116 | Journal | ACS Chem Biol | Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. | 23,683,440 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,682 | lysine demethylase 5C | 8,979 | GSK-J4 | Synthetic organic | 83,294 | Inhibitor | Inhibition | false | 310,264,759 | false | 4.82 | pIC50 | 30,418 | Journal | Nature | Inhibition of demethylases by GSK-J1/J4. | 25,279,926 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,682 | lysine demethylase 5C | 7,027 | GSK-J1 | Synthetic organic | 83,293 | Inhibitor | Inhibition | false | 178,103,606 | false | 6.26 | pIC50 | 30,418 | Journal | Nature | Inhibition of demethylases by GSK-J1/J4. | 25,279,926 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,681 | lysine demethylase 5B | 7,026 | PBIT | Synthetic organic | 79,349 | Inhibitor | Inhibition | false | 178,103,605 | false | 5.52 | pIC50 | 24,166 | Journal | J Biol Chem | Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. | 23,408,432 | null | PMC3611010 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,681 | lysine demethylase 5B | 8,576 | KDOAM25 | Synthetic organic | 89,969 | Inhibitor | Inhibition | false | 252,166,777 | false | 7.72 | pIC50 | 45,914 | Journal | Cell Chem Biol | Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells. | 28,262,558 | null |
||
869 | enzyme | 1.14.11.- Histone demethylases | 2,681 | lysine demethylase 5B | 10,141 | KDM5 inhibitor N71 | Synthetic organic | 85,719 | Inhibitor | Irreversible inhibition | false | 381,118,851 | true | 6.66 | pIC50 | 36,398 | Journal | J Med Chem | Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A. | 30,392,349 | null | PMC6467790 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,681 | lysine demethylase 5B | 8,979 | GSK-J4 | Synthetic organic | 83,292 | Inhibitor | Inhibition | false | 310,264,759 | false | 5.01 | pIC50 | 30,418 | Journal | Nature | Inhibition of demethylases by GSK-J1/J4. | 25,279,926 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,681 | lysine demethylase 5B | 7,027 | GSK-J1 | Synthetic organic | 83,291 | Inhibitor | Inhibition | false | 178,103,606 | false | 6.77 | pIC50 | 30,418 | Journal | Nature | Inhibition of demethylases by GSK-J1/J4. | 25,279,926 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,681 | lysine demethylase 5B | 10,083 | Compound 9 [doi:10.26434/chemrxiv.7072592.v1] | Synthetic organic | 85,544 | Inhibitor | Inhibition | false | 375,973,270 | true | 6.52 | pIC50 | 36,158 | Journal | Angew Chem Int Ed Engl | Design, Synthesis and Characterization of Covalent KDM5 Inhibitors. | 30,431,220 | 10.26434/chemrxiv.7072592.v1 | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,680 | lysine demethylase 5A | 7,026 | PBIT | Synthetic organic | 79,350 | Inhibitor | Inhibition | false | 178,103,605 | false | 5.22 | pIC50 | 24,166 | Journal | J Biol Chem | Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. | 23,408,432 | null | PMC3611010 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,680 | lysine demethylase 5A | 10,141 | KDM5 inhibitor N71 | Synthetic organic | 85,718 | Inhibitor | Irreversible inhibition | false | 381,118,851 | true | 6.49 | pIC50 | 36,398 | Journal | J Med Chem | Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A. | 30,392,349 | null | PMC6467790 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,680 | lysine demethylase 5A | 7,027 | GSK-J1 | Synthetic organic | 83,290 | Inhibitor | Inhibition | false | 178,103,606 | false | 5.17 | pIC50 | 30,418 | Journal | Nature | Inhibition of demethylases by GSK-J1/J4. | 25,279,926 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,679 | lysine demethylase 4E | 9,584 | ML324 | Synthetic organic | 84,387 | Inhibitor | Inhibition | false | 340,590,215 | false | 6.04 | pIC50 | 33,194 | Journal | Probe Reports from the NIH Molecular Libraries Program | Discovery of ML324, a JMJD2 demethylase inhibitor with demonstrated antiviral activity | 24,260,783 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,679 | lysine demethylase 4E | 8,744 | compound 6a [PMID: 18942826] | Synthetic organic | 82,695 | Inhibitor | Inhibition | false | 252,827,402 | false | 5.85 | pIC50 | 29,703 | Journal | J Med Chem | Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. | 18,942,826 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,677 | lysine demethylase 4C | 12,807 | zavondemstat | Synthetic organic | 89,917 | Inhibitor | Inhibition | false | 483,123,355 | false | null | pIC50 | 45,828 | Patent | null | Histone demethylase inhibitors | null | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,677 | lysine demethylase 4C | 8,230 | IOX1 | Synthetic organic | 81,841 | Inhibitor | Inhibition | false | 249,565,910 | false | 6.22 | pIC50 | 27,117 | Journal | ChemMedChem | A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. | 24,504,543 | null | PMC4503230 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,675 | lysine demethylase 4A | 9,584 | ML324 | Synthetic organic | 84,388 | Inhibitor | Inhibition | false | 340,590,215 | false | 6 | pIC50 | 33,194 | Journal | Probe Reports from the NIH Molecular Libraries Program | Discovery of ML324, a JMJD2 demethylase inhibitor with demonstrated antiviral activity | 24,260,783 | null | null |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,675 | lysine demethylase 4A | 10,141 | KDM5 inhibitor N71 | Synthetic organic | 85,720 | Inhibitor | Inhibition | false | 381,118,851 | false | 5.28 | pIC50 | 36,398 | Journal | J Med Chem | Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A. | 30,392,349 | null | PMC6467790 |
|
869 | enzyme | 1.14.11.- Histone demethylases | 2,675 | lysine demethylase 4A | 8,744 | compound 6a [PMID: 18942826] | Synthetic organic | 82,694 | Inhibitor | Inhibition | false | 252,827,402 | false | 6.15 | pIC50 | 29,703 | Journal | J Med Chem | Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. | 18,942,826 | null | null |
|
923 | enzyme | 1.14.13.9 Kynurenine 3-monooxygenase | 2,886 | kynurenine 3-monooxygenase | 10,358 | GSK065 | Synthetic organic | 86,320 | Inhibitor | Inhibition | false | 384,403,639 | false | 10.3 | pKi | 37,581 | Journal | Nat Commun | Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. | 28,604,669 | PMC5477544 |
||
923 | enzyme | 1.14.13.9 Kynurenine 3-monooxygenase | 2,886 | kynurenine 3-monooxygenase | 10,358 | GSK065 | Synthetic organic | 86,319 | Inhibitor | Inhibition | false | 384,403,639 | false | 8.6 | pIC50 | 37,581 | Journal | Nat Commun | Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. | 28,604,669 | PMC5477544 |
||
923 | enzyme | 1.14.13.9 Kynurenine 3-monooxygenase | 2,886 | kynurenine 3-monooxygenase | 9,007 | GSK180 | Synthetic organic | 83,368 | Inhibitor | Inhibition | false | 310,264,785 | true | 8.2 | pIC50 | 30,503 | Journal | Nat Med | Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis. | 26,752,518 | null | PMC4871268 |
|
877 | enzyme | 1.17.4.1 Ribonucleoside-diphosphate reductases | 2,630 | ribonucleotide reductase catalytic subunit M1 | 6,802 | clofarabine | Synthetic organic | 78,910 | Inhibitor | Inhibition | true | FDA (2004), EMA (2009) | 178,103,408 | false | 8.3 | pIC50 | 23,352 | Journal | Cancer Res | Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. | 1,707,752 | null | null |
877 | enzyme | 1.17.4.1 Ribonucleoside-diphosphate reductases | 2,630 | ribonucleotide reductase catalytic subunit M1 | 4,802 | fludarabine | Synthetic organic | 78,912 | Inhibitor | Inhibition | true | FDA (1991) | 178,101,504 | true | 6 | pIC50 | 23,353 | Journal | Mol Pharmacol | In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. | 7,048,062 | null | null |
877 | enzyme | 1.17.4.1 Ribonucleoside-diphosphate reductases | 2,630 | ribonucleotide reductase catalytic subunit M1 | 4,793 | gemcitabine | Synthetic organic | 78,905 | Inhibitor | Inhibition | true | FDA (1996) | 178,101,495 | true | null | - | 23,348 | Journal | Mol Pharmacol | Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. | 2,233,693 | null | null |
877 | enzyme | 1.17.4.1 Ribonucleoside-diphosphate reductases | 2,630 | ribonucleotide reductase catalytic subunit M1 | 6,822 | hydroxyurea | Synthetic organic | 78,907 | Inhibitor | Inhibition | true | FDA (1967), EMA (2007) | 178,103,428 | true | 3.83 | pIC50 | 23,349 | Journal | Biochem Pharmacol | Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay. | 15,670,581 | null | null |
877 | enzyme | 1.17.4.1 Ribonucleoside-diphosphate reductases | 2,630 | ribonucleotide reductase catalytic subunit M1 | 12,113 | TAS1553 | Synthetic organic | 88,838 | Inhibitor | Binding | false | 472,319,235 | false | 7.46 | pKd | 43,979 | Journal | Commun Biol | TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress. | 35,681,099 | null |
||
877 | enzyme | 1.17.4.1 Ribonucleoside-diphosphate reductases | 2,631 | ribonucleotide reductase regulatory subunit M2 | 6,802 | clofarabine | Synthetic organic | 78,911 | Inhibitor | Inhibition | true | FDA (2004), EMA (2009) | 178,103,408 | true | 8.3 | pIC50 | 23,352 | Journal | Cancer Res | Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. | 1,707,752 | null | null |
877 | enzyme | 1.17.4.1 Ribonucleoside-diphosphate reductases | 2,631 | ribonucleotide reductase regulatory subunit M2 | 4,802 | fludarabine | Synthetic organic | 78,913 | Inhibitor | Inhibition | true | FDA (1991) | 178,101,504 | true | 6 | pIC50 | 23,353 | Journal | Mol Pharmacol | In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. | 7,048,062 | null | null |
877 | enzyme | 1.17.4.1 Ribonucleoside-diphosphate reductases | 2,631 | ribonucleotide reductase regulatory subunit M2 | 4,793 | gemcitabine | Synthetic organic | 78,906 | Inhibitor | Inhibition | true | FDA (1996) | 178,101,495 | true | null | - | 23,348 | Journal | Mol Pharmacol | Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. | 2,233,693 | null | null |
877 | enzyme | 1.17.4.1 Ribonucleoside-diphosphate reductases | 2,631 | ribonucleotide reductase regulatory subunit M2 | 6,822 | hydroxyurea | Synthetic organic | 78,908 | Inhibitor | Inhibition | true | FDA (1967), EMA (2007) | 178,103,428 | true | 3.83 | pIC50 | 23,349 | Journal | Biochem Pharmacol | Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay. | 15,670,581 | null | null |
1,068 | enzyme | 1.2.3.1 Aldehyde oxidase | 3,186 | aldehyde oxidase 1 | 2,820 | raloxifene | Synthetic organic | 89,776 | Inhibitor | Inhibition | true | FDA (1997), EMA (1998) | 135,650,883 | false | 7.35 | pIC50 | 45,530 | Patent | null | Therapeutic agent for nonalcoholic fatty liver disease | null | null | null |
912 | enzyme | 1.4.3.13 Lysyl oxidases | 3,097 | lysyl oxidase | 10,485 | CCT365623 | Synthetic organic | 86,766 | Inhibitor | Inhibition | false | 385,612,244 | false | 6.05 | pIC50 | 38,259 | Journal | J Med Chem | Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships. | 31,070,916 | null |
||
912 | enzyme | 1.4.3.13 Lysyl oxidases | 3,097 | lysyl oxidase | 10,486 | compound 21b [PMID: 31430136] | Synthetic organic | 86,767 | Inhibitor | Inhibition | false | 385,612,245 | false | 5.48 | pIC50 | 38,256 | Journal | J Med Chem | 2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth. | 31,430,136 | null | PMC7073924 |
|
912 | enzyme | 1.4.3.13 Lysyl oxidases | 2,853 | lysyl oxidase like 2 | 10,485 | CCT365623 | Synthetic organic | 86,768 | Inhibitor | Inhibition | false | 385,612,244 | false | 5.82 | pIC50 | 38,259 | Journal | J Med Chem | Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships. | 31,070,916 | null |
||
912 | enzyme | 1.4.3.13 Lysyl oxidases | 2,853 | lysyl oxidase like 2 | 10,486 | compound 21b [PMID: 31430136] | Synthetic organic | 86,769 | Inhibitor | Inhibition | false | 385,612,245 | true | 6.82 | pIC50 | 38,256 | Journal | J Med Chem | 2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth. | 31,430,136 | null | PMC7073924 |
|
912 | enzyme | 1.4.3.13 Lysyl oxidases | 2,853 | lysyl oxidase like 2 | 8,412 | simtuzumab | Antibody | 82,117 | Inhibitor | Inhibition | false | 252,166,622 | true | 7.17 | pKi | 27,880 | Patent | null | LOX and LOXL2 inhibitors and uses thereof. | null | null | null |
|
84 | nhr | 1A. Thyroid hormone receptors | 588 | Thyroid hormone receptor-α | 2,639 | sobetirome | Synthetic organic | 6,262 | Agonist | Agonist | false | 135,650,297 | null | 9.36 | pKd | 10,040 | Journal | Mol Endocrinol | Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. | 2,158,622 | null | null |
|
84 | nhr | 1A. Thyroid hormone receptors | 588 | Thyroid hormone receptor-α | 2,636 | rT<sub>3</sub> | Synthetic organic | 6,260 | Agonist | Agonist | false | 135,650,897 | null | null | pIC50 | 10,040 | Journal | Mol Endocrinol | Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. | 2,158,622 | null | null |
|
84 | nhr | 1A. Thyroid hormone receptors | 588 | Thyroid hormone receptor-α | 12,026 | resmetirom | Synthetic organic | 88,707 | Agonist | Agonist | true | FDA (2024) | 464,244,167 | false | 5.43 | pEC50 | 43,758 | Journal | J Med Chem | Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia. | 24,712,661 | null |
|
84 | nhr | 1A. Thyroid hormone receptors | 588 | Thyroid hormone receptor-α | 2,633 | NH-3 | Synthetic organic | 6,257 | Antagonist | Antagonist | false | 135,650,713 | null | 7.62 | pKd | 10,041 | Journal | J Med Chem | Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. | 12,109,914 | null | null |
|
84 | nhr | 1A. Thyroid hormone receptors | 588 | Thyroid hormone receptor-α | 2,638 | KB-141 | Synthetic organic | 6,263 | Agonist | Agonist | false | 135,650,452 | null | 7.6 | pIC50 | 10,066 | Journal | J Med Chem | Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. | 12,699,376 | null | null |
|
84 | nhr | 1A. Thyroid hormone receptors | 588 | Thyroid hormone receptor-α | 6,951 | dextrothyroxine | Synthetic organic | 79,001 | Agonist | Agonist | true | FDA (1967) | 178,103,533 | true | null | - | 23,507 | Journal | J Clin Endocrinol Metab | Effects of dextrothyroxine on the pituitary-thyroid axis in hypercholesterolemic children and goitrous adults. | 6,777,394 | null | null |
Dataset Card for dwb2023/family-target-interaction-ligand-gtopdb
Dataset Details
Dataset Description
Dataset created using the IUPHAR database from the Guide to Pharmacology website
Dataset Sources
- Repository: https://www.guidetopharmacology.org/DATA/public_iuphardb_v2024.2.zip
- Paper: https://academic.oup.com/nar/article/52/D1/D1438/7332061?login=false
Dataset Creation
Source Data
Query used to create the dataset:
SELECT f.family_id,
f.type AS family_type,
f.name AS family_name,
o.object_id AS target_id,
o.name AS target_name,
l.ligand_id,
l.name AS ligand_name,
l.type AS ligand_type,
i.interaction_id,
i.type AS interaction_type,
i.action AS interaction_action,
l.approved AS ligand_approved,
l.approved_source AS ligand_approval_source,
l.pubchem_sid AS ligand_pubchem_sid,
i.primary_target AS interaction_primary_target,
i.affinity_median AS interaction_affinity_median,
i.affinity_units AS interaction_affinity_units,
r.reference_id,
r.type AS reference_type,
r.title AS reference_title,
r.article_title AS reference_article_title,
r.pubmed_id AS reference_pubmed_id,
r.doi AS reference_doi,
r.pmc_id AS reference_pmc_id
FROM object o
JOIN receptor2family rf ON o.object_id = rf.object_id
JOIN family f ON rf.family_id = f.family_id
JOIN interaction i ON o.object_id = i.object_id
JOIN ligand l ON i.ligand_id = l.ligand_id
LEFT JOIN interaction_affinity_refs ia ON i.interaction_id = ia.interaction_id
LEFT JOIN reference r ON ia.reference_id = r.reference_id
ORDER BY f.type, f.name, o.name, l.name;
Citation
BibTeX:
@article{10.1093/nar/gkad944,
author = {Harding, Simon D and Armstrong, Jane F and Faccenda, Elena and Southan, Christopher and Alexander, Stephen P H and Davenport, Anthony P and Spedding, Michael and Davies, Jamie A},
title = "{The IUPHAR/BPS Guide to PHARMACOLOGY in 2024}",
journal = {Nucleic Acids Research},
volume = {52},
number = {D1},
pages = {D1438-D1449},
year = {2023},
month = {10},
abstract = "{The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb; https://www.guidetopharmacology.org) is an open-access, expert-curated, online database that provides succinct overviews and key references for pharmacological targets and their recommended experimental ligands. It includes over 3039 protein targets and 12 163 ligand molecules, including approved drugs, small molecules, peptides and antibodies. Here, we report recent developments to the resource and describe expansion in content over the six database releases made during the last two years. The database update section of this paper focuses on two areas relating to important global health challenges. The first, SARS-CoV-2 COVID-19, remains a major concern and we describe our efforts to expand the database to include a new family of coronavirus proteins. The second area is antimicrobial resistance, for which we have extended our coverage of antibacterials in partnership with AntibioticDB, a collaboration that has continued through support from GARDP. We discuss other areas of curation and also focus on our external links to resources such as PubChem that bring important synergies to the resources.}",
issn = {0305-1048},
doi = {10.1093/nar/gkad944},
url = {https://doi.org/10.1093/nar/gkad944},
eprint = {https://academic.oup.com/nar/article-pdf/52/D1/D1438/55039511/gkad944.pdf},
}
Glossary
Here's a glossary for the dataset dwb2023/family_target_ligand_gtopdb
based on the dataset description and the SQL query provided:
Glossary
family_id: Unique identifier for a family in the IUPHAR database. A family groups related pharmacological targets based on their function or structure.
family_type: The classification type of the family. This could refer to the specific category or class the family belongs to within the broader pharmacological context.
family_name: The name of the family, which provides a descriptive label for the group of related targets.
target_id: Unique identifier for a target in the IUPHAR database. A target is a biological entity, such as a receptor or enzyme, that a ligand interacts with.
target_name: The name of the target, describing the specific protein or molecule that a ligand can bind to or influence.
interaction_id: A unique identifier for an interaction in the IUPHAR database. An interaction refers to the relationship between a ligand and a target, where the ligand binds to or affects the target in some way.
interaction_type: The type of interaction occurring between the ligand and the target. This might describe whether the interaction is inhibitory, stimulatory, or another type of effect that the ligand has on the target.
interaction_action: The specific action that the ligand exerts on the target, such as activation, inhibition, modulation, or binding.
ligand_id: Unique identifier for a ligand in the IUPHAR database. A ligand is a substance (such as a drug, hormone, or neurotransmitter) that forms a complex with a biomolecule to serve a biological purpose.
ligand_name: The name of the ligand, describing the specific molecule that interacts with the target.
ligand_type: The classification type of the ligand, which describes the nature of the ligand (e.g., small molecule, peptide, antibody, etc.).
ligand_approved: A boolean indicator (True/False) that specifies whether the ligand has been approved by regulatory authorities for therapeutic use.
ligand_approval_source: The source or agency that approved the ligand for therapeutic use, such as the FDA (Food and Drug Administration) or EMA (European Medicines Agency).
ligand_pubchem_sid: The Substance ID (SID) in the PubChem database, which provides a unique identifier for substances recorded in PubChem. It links to detailed chemical and biological information about the ligand.
interaction_primary_target: A boolean indicator (True/False) that specifies whether the target is the primary target for the ligand in the context of the recorded interaction. The primary target is usually the main biological entity that the ligand is designed to influence.
interaction_affinity_median: The median value of the affinity data for the interaction, usually expressed as a numerical value that indicates how strongly the ligand binds to the target. Affinity is often measured in terms of concentration, such as in nanomolar (nM) units.
interaction_affinity_units: The units in which the affinity of the ligand for the target is measured, such as nanomolar (nM), micromolar (μM), or other relevant concentration units.
reference_id: A unique identifier for the reference or source of information about the interaction or ligand in the IUPHAR database.
reference_type: The type or category of the reference, which could indicate whether it's a journal article, book, database entry, or another form of scientific literature.
reference_title: The full title of the reference, which provides a brief description of the content of the source.
reference_article_title: The title of the specific article within a larger publication, if applicable. This may be the same as the reference_title for journal articles.
reference_pubmed_id: The unique identifier assigned to the reference in PubMed, a free full-text archive of biomedical and life sciences journal literature. This allows for easy lookup of the reference in the PubMed database.
reference_doi: The Digital Object Identifier (DOI) for the reference, which is a persistent and unique identifier for the document that allows for reliable linking to its online location.
reference_pmc_id: The unique identifier for the reference in PubMed Central (PMC), which is a free full-text archive of biomedical and life sciences journal literature at the U.S. National Institutes of Health's National Library of Medicine (NIH/NLM).
- Downloads last month
- 32